CSF biomarkers in patients with epilepsy in Alzheimer’s disease: a nation-wide study
Open Access
- 17 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (4) , fcac210
Abstract
Alzheimer’s disease is the most common neurodegenerative dementia. A subset of Alzheimer’s disease patients develop epilepsy. The risk is higher in young-onset Alzheimer’s disease, but pathophysiological mechanisms remain elusive. The purpose of this study was to assess biomarkers reflecting neurodegeneration in Alzheimer’s disease patients with and without epilepsy. By cross-referencing the largest national laboratory database with Swedish National Patient Register, we could identify CSF biomarker results from 17901 Alzheimer’s disease patients, and compare levels of neurofilament light, glial fibrillary acidic protein, total tau, phosphorylated tau and amyloid beta 42 in patients with (n = 851) and without epilepsy. The concentrations of total tau and phosphorylated tau were higher in Alzheimer’s disease patients with epilepsy than Alzheimer’s disease patients without epilepsy and amyloid beta 42 levels were significantly lower in Alzheimer’s disease patients with epilepsy. No differences in the levels of neurofilament light and glial fibrillary acidic protein were observed. Our study suggests that epilepsy is more common in Alzheimer’s disease patients with more pronounced Alzheimer’s pathology, as determined by the CSF biomarkers. Further studies are needed to investigate the biomarker potential of these CSF markers as predictors of epilepsy course or as indicators of epileptogenesis in Alzheimer’s disease.Keywords
Funding Information
- Swedish Society for Medical Research (#S18-0050)
- Swedish Society of Medicine (#SLS-881501)
- ALF Västra Götaland (#ALFGBG 932515)
- Wallenberg Scholar
- Swedish Research Council (#2018-02532)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- Alzheimer Drug Discovery Foundation (#201809-2016862)
- AD strategic fund
- Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C)
- Olav Thon Foundation
- Erling-Persson Family Foundation
- Stiftelsen för Gamla Tjänarinnor (#FO2019-0228)
- Marie Skłodowska-Curie (860197)
- European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694)
- UK Dementia Research Institute
This publication has 31 references indexed in Scilit:
- Epileptic Seizures in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2016
- Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease ProgressionJAMA Neurology, 2016
- Astrogliosis as a therapeutic target for neurodegenerative diseasesNeuroscience Letters, 2014
- Seizures and Epileptiform Activity in the Early Stages of Alzheimer DiseaseJAMA Neurology, 2013
- Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor ProteinScience Translational Medicine, 2013
- Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?Journal of Alzheimer’s Disease, 2012
- Age and diagnostic performance of Alzheimer disease CSF biomarkersNeurology, 2012
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy studyNeurology, 2003
- A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adultsJournal of Neuroscience Methods, 1994